Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study

PURPOSE: Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who...

Descripción completa

Detalles Bibliográficos
Autores principales: Hur, Joon Young, Kim, Youjin, Kwon, Ghee-Young, Kang, Minyong, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Lee, Su Jin, Park, Se Hoon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790849/
https://www.ncbi.nlm.nih.gov/pubmed/30653744
http://dx.doi.org/10.4143/crt.2018.604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790849/
https://www.ncbi.nlm.nih.gov/pubmed/30653744
http://dx.doi.org/10.4143/crt.2018.604

Ejemplares similares